Circulating tumor cells detection and evaluation of their apoptotic status in patients with localized breast cancer before and after surgery.
M. Bertolin, Andrea Amadori, Rita Zamarchi(Istituto Oncologico Veneto), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Cristina Magro, Silvia Michieletto(Istituto Oncologico Veneto), Jacopo Pigozzo(Istituto Oncologico Veneto), Fernando A. Bozza(D’Or Institute for Research and Education), Antonio Jirillo, Sérgio Valente(Sapienza University of Rome), H. Koussis, E. Rossi, Cristina Ghiotto(Istituto Oncologico Veneto)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k